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Abstract
AIM
To determine factors independently influencing response 
to ingenol mebutate therapy and assess efficacy on 
clinical setting of non­hypertrophic non­hyperkeratotic 
actinic keratosis (AK).
METHODS
Consecutive patients affected by non­hypertrophic non­
hyperkeratotic AKs of the face or scalp were enrolled 
to receive ingenol mebutate 0.015% gel on a selected 
skin area of 25 cm2 for 3 consecutive days. Local skin 
reactions were calculated at each follow up visit using a 
validated composite score. Efficacy was evaluated by the 
comparison of clinical and dermoscopic pictures before 
the treatment and at day 57, and classified as complete, 
partial and poor response.
RESULTS
A number of 130 patients were enrolled, of which 101 
(77.7%) were treated on the face, while 29 (22.3%) on 
the scalp. The great majority of our study population 
(n = 119, 91.5%) reached at least a 75% clearance of 
AKs and, in particular, 58 patients (44.6%) achieved 
a complete response while 61 (46.9%) a partial one. 
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Logistic backward multivariate analysis showed that facial 
localization, level of local skin reaction (LSR) at day 2, 
the highest LSR values and level of crusts at day 8 were 
factors independently associated with the achievement of 
a complete response.
CONCLUSION
Ingenol mebutate 0.015% gel, when properly applied, is 
more effective on the face than on the scalp and efficacy 
is directly associated to LSR score.
Key words: Ingenol mebutate; Actinic keratosis; Facial 
and scalp lesions; Skin reactions; Dermoscopic feature
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Core tip: Ingenol mebutate 0.015% gel is an effective 
treatment for non­hypertrophic non­hyperkeratotic actinic 
keratosis of face and scalp. Facial lesions are more prone 
to achieve a complete response to this therapy than those 
located on the scalp. Facial localization and the highest 
levels of local skin reaction, in particular the amount of 
crusting, are predictive for complete response to ingenol 
mebutate 0.015% gel therapy in a real clinical setting.
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INTRODUCTION
For a long time dermatologists have questioned if actinic 
keratosis (AK) should be considered as a precancerous 
lesion or an early squamous cell carcinoma (SCC). Apart 
from academic debate, it is actually clear that AKs have 
a low but definite potential to become invasive and even 
metastatic and that this risk increases over time[1].
Since it is impossible to predict which AK will pro­
gress to SCC and given the high prevalence of AKs in 
people with fair photo­types, chronically exposed to 
ultraviolet (UV) rays, treatment is recommended[2].
Conventional treatments for AK include cryotherapy, 
laser­therapy, surgical excision, photodynamic therapy, 
diclofenac 3% gel, imiquimod 5% and 5­fluorouracil 
creams[3,4].
Ingenol mebutate 0.015% gel, obtained by the sap of 
the plant Euphorbia peplus, has been recently approved 
in Europe for the treatment of non­hypertrophic non­
hyperkeratotic AKs of face and scalp, which mainly 
correspond to Ⅰ and Ⅱ histopathologic categories[5,6].
The mechanism of action of ingenol mebutate has 
been partially explained with a rapid cytotoxic activity at 
higher concentration and with the activation of immune 
system at lower concentration[7]. The long­lasting 
immune surveillance and the clearance of single tumour 
cell clones within cancerization field, could justify the 
low recurrence rates of AKs observed after treatment[8].
To the best of our knowledge, no studies have as­
sessed factors independently influencing the response 
to ingenol mebutate therapy. Efficacy data of phase Ⅲ 
trials have not been widely confirmed on a large real 
clinical setting to date[9­11].
These studies reported a higher efficacy of ingenol 
mebutate 0.015% gel in patients experiencing more 
severe local skin reactions (LSRs); however they didn’t 
investigate how the single components of the composite 
LSR score could influence the response to treatment.
We conducted a prospective study to determine which 
factors, among age, gender, head site and LSR score, 
could independently predict the response to 0.015% 
ingenol mebutate treatment and to assess the efficacy of 
this therapy in a real clinical setting.
MATERIALS AND METHODS
Study population
We (GLV and RP) enrolled consecutive patients, aged ≥ 
18 years, affected by non­hypertrophic non­hyperkeratotic 
AKs of face and scalp, who were attending our outpatient 
clinic from April 2014 to March 2015.
The diagnosis of AK was performed both clinically and 
dermoscopically, respectively based on the presence of 
erythematous macular lesions with or without a slightly 
scaly surface, and on the identification of the typical 
red pseudonetwork, corresponding to grade Ⅰ AK, or 
strawberry pattern, corresponding to grade Ⅱ AK[12].
The presence of a skin cancer other than AK in 
the selected skin area was considered as an exclusion 
criteria. Furthermore, if at least one AK of the selected 
area had been treated by non­ablative methods within 
the previous year, patient was excluded from the study.
Treatment procedure
Ingenol mebutate 0.015% gel was applied by the same 
physician (GLV) for 3 consecutive days on a selected 
skin area of 25 cm2, which included 4 to 8 AKs.
Each enrolled patient gave written informed consent 
for clinical and dermoscopic digital documentation and 
the ethical committee approval was waived.
Outcome assessment
Clinical and dermoscopic pictures were collected at 
baseline and at each control visit (day 2, 3, 8, 15, 29 
and 57).
Local skin reactions (LSR) score was calculated at 
each control visit, using a validated composite score 
(ranging from 0 to 24) given by the sum of 6 single 
scores for erythema, flaking/scaling, crusting, swelling, 
vesiculation/pustulation and erosion/ulceration; with 
grade 0 representing no reaction while grade 4 indicating 
a skin reaction extending beyond the treated are[13].
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Efficacy was evaluated comparing clinical and dermo­
scopic pictures at baseline and at day 57 and response 
was classified as complete, partial (≥ 75% clearance) or 
poor (< 75% clearance). 
Statistical analysis
Statistical analyses were performed using the IBM SPSS 
21.0 package (Statistical Package for Social Sciences, 
SPSS Inc., Chicago, Ill.).
Data is expressed as mean standard deviation. To 
analyse factors influencing efficacy of 0.015% ingenol 
mebutate therapy, we used Spearman’s rho coefficient to 
assess significant correlations, which were subsequently 
quantified via univariate logistic regression. Furthermore, 
a logistic multivariate regression backward model was 
constructed to identify major independent factors that 
showed a significant difference (P < 0.10) on univariate 
analysis, that have an influence on complete response. 
The statistical significance was set at P < 0.05.
RESULTS 
Study population and efficacy data
Demographic and efficacy data are listed in Table 1. 
A number of 130 patients were enrolled, 91 (70.0%) 
were males and 39 (30.0%) were females, with a 
mean age (standard deviation) of 72.2 (10.3) years. 
All the patients completed the 3 applications of ingenol 
mebutate 0.015% gel, as scheduled; the majority, 101 
(77.7%) were treated on the face, while 29 (22.3%) on 
the scalp.
Regarding efficacy, the great majority of our study 
population (119, 91.5%) reached at least a 75% 
clearance of AKs, in particular 58 patients (44.6%) 
achieved a complete response and 61 (46.9%) a partial 
one; while poor responders were only 11 (8.5%).
Figure 1 shows the clinical and dermoscopic pictures 
of a patient treated on the scalp, before and after the 
therapy.
Local skin reaction data
Figure 2 and Table 2 report data about the "number of 
patients with positive scores" and "mean values" of LSR 
composite and single scores at each follow up visit. 
Each patient enrolled experienced at least one LSR, 
but no one reported systemic symptoms.
The highest number of patients involved and the 
highest mean scores were reached at day 3 for both 
composite and all single scores, with the exception of 
crusting and flaking/scaling, reaching the highest level 
at day 8 and 15, respectively.
These 2 components were the less represented at 
day 2 [4 patients (3.1%) had flaking/scaling and only 
2 (1.5%) had crusts, with mean values of 0.05 ± 0.28 
and 0.02 ± 0.12, respectively] and totally disappeared 
in the whole population since day 57.
Erythema was the only LSR component involving 
the entire study population (at day 2 and 3) and the 
only, still present at day 57 in 49 patients (37.7%), with 
a mean score of 0.38 ± 0.50.
Swelling reached the highest levels at day 2 and 3 
[114 (87.7%) and 125 (96.2%) patients, with 1.48 ± 
0.82 and 2.38 ± 1.08 mean scores, respectively], but 
quickly reduced afterward, becoming totally absent 
since day 57.
Grade 4 swelling was observed in 23 (17.7%) 
patients and presented as periorbital edema following 
the application of ingenol mebutate gel on forehead and 
temporal areas; it resolved within day 15 in all cases.
Vesiculation/pustulation were the first signs to 
Table 1  Demographic and response data of the whole study 
population n  (%)
Factors Value
Age (yr), mean ± SD 72.2 ± 10.3
Gender M   91 (70)
F   39 (30)
Total 130
Head site Face 101 (77.7)
Scalp   29 (22.3)
Total 130
Response Poor   11 (8.5)
Partial     61 (46.9)
Complete     58 (44.6)
Total 130
Figure 1  Patient treated with ingenol mebutate for actinic keratosis of the 
scalp. A and C: Clinical images of the treated area before and after (day 57) the 
therapy, respectively; B: Local skin reaction to ingenol mebutate at day 8 showing 
a grade 3 crusting reaction and erythema exceeding the treated area (grade 4); D: 
Dermoscopic image of an actinic keratosis of the treated area at baseline showing 
red pseudonetwork and scaling in the central area; E:  Dermoscopic picture of the 
same skin area at day 57 showing the complete disappearance of the preexisting 
actinic keratosis.
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disappear, being widely present at day 2 and 3 [102 
(78.5%) and 123 (94.6%) patients, with 1.48 ± 0.93 
and 2.45 ± 0.86 mean scores, respectively], but only 
observable in 8 patients (6.2%) at day 8 and completely 
absent since day 15.
Ulceration was the least observed LSR component, 
being present in a maximum of 43 patients (33.1%) at 
day 3 and early disappearing in the entire population 
since day 29.
Spearman’s correlation
Spearman rho analysis highlighted significant correlations 
among response and gender, head site and the maxi­
mum level of the LSR composite score (ρ = 0.189, P = 
0.031; ρ = ­0.258, P = 0.003; ρ = 0.449, P < 0.001, 
respectively).
Furthermore, all the maximum levels of single scores, 
but flaking/scaling, resulted to be correlated to response 
(erythema: ρ = 0.351, P < 0.001; vesiculation: ρ = 0.329, 
P < 0.001; crusting: ρ = 0.255, P = 0.003; swelling: ρ = 
0.365, P < 0.001; ulceration: ρ = 0.194, P = 0.027).
Regarding the single follow up visits, a significant 
correlation with response was reported for LSR 
composite score at day 2, 3, 8 and 15 (ρ = 0.455, P < 
0.001; ρ = 0.484, P < 0.001; ρ = 0.325, P < 0.001; 
ρ = 0.234, P = 0.007, respectively), for erythema at 
every follow up visit (day 2: ρ = 0.400, P < 0.001; day 
3: ρ = 0.351, P < 0.001; day 8: ρ = 0.314, P < 0.001; 
day 15: ρ = 0.270, P = 0.002; day 29: ρ = 0.282, P 
= 0.001; day 57: ρ = 0.189, P = 0.032), for crusting, 
swelling, vesiculation/pustulation and ulceration at days 
3 (ρ = 0.180, P = 0.041; ρ = 0.372, P < 0.001; ρ = 
0.329, P < 0.001; ρ = 0.215, P = 0.014, respectively) 
for swelling and vesiculation at day 2 (ρ = 0.357, P 
< 0.001; ρ = 0.418, P < 0.001, respectively) and for 
crusting and swelling at day 8 (ρ = 0.288, P = 0.001; ρ 
= 0.237, P = 0.007, respectively).
Univariate analysis
The univariate logistic regression analysis confirmed 
that the factors highlighted by Spearman’s correlation 
were all good predictors of complete response to 
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Figure 2  Number of skin reactions and scores at each follow up visit. A: The number and features of different skin reactions over the time; B: Mean values 
describing the severity of each skin reaction and the LSR composite score (light blue line). Skin reactions included: Erythema (blue), flaking/scaling (red), crusting 
(green), swelling (purple), vesiculation/pustulation (light blue), and ulceration (orange). LSR: Local skin reaction.
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Table 2  Number of patients with positive scores and mean values of local skin reaction composite and single scores at each follow 
up visit
Day 2 Day 3 Day 8 Day 15 Day 29 Day 57
Erythema n (%) 130 (100) 130 (100)  129 (99.2)    128 (98.5)   107 (82.3) 49 (37.7)
mean ± SD 1.82 ± 0.68 2.87 ± 0.58 2.38 ± 0.78 1.86 ± 0.81 1.19 ± 0.77 0.38 ± 0.50
Flaking/scaling n (%)    4 (3.1)  12 (9.2)    55 (42.3)    112 (86.2)     45 (34.6) 0
mean ± SD 0.05 ± 0.28 0.11 ± 0.39 0.78 ± 1.00 1.49 ± 0.87 0.43 ± 0.65 0
Crusting n (%)    2 (1.5)    18 (13.8)  116 (89.2)      57 (43.8)     9 (6.9) 0
mean ± SD 0.02 ± 0.12 0.17 ± 0.45 2.16 ± 0.98  0.65 ± 0.89 0.10 ± 0.39 0
Swelling n (%)  114 (87.7)  125 (96.2)    71 (54.6)    11 (8.5)     2 (1.5) 0
mean ± SD 1.48 ± 0.82 2.38 ± 1.08 0.85 ± 0.98 0.13 ± 0.55 0.02 ± 0.12 0
Vesiculation/pustulation n (%)  102 (78.5)  123 (94.6)    8 (6.2) 0 0 0
mean ± SD 1.48 ± 0.93 2.45 ± 0.86 0.06 ± 0.24 0 0 0
Ulceration n (%)    5 (3.8)    43 (33.1)    22 (16.9)      5 (3.8) 0 0
mean ± SD 0.04 ± 0.19 0.48 ± 0.74 0.36 ± 0.90 0.08 ± 0.45 0 0
LSR composite mean ± SD 4.89 ± 2.14 8.43 ± 2.38 6.62 ± 2.44 4.25 ± 1.72 1.66 ± 1.28 0.35 ± 0.49
LSR: Local skin reaction.
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ingenol mebutate 0.015% therapy, with the exclusion of 
crusting at day 3 and the highest values of ulceration (OR 
= 2.32, 95%CI: 0.99­5.46, P = 0.053 and OR = 1.35, 
95%CI: 0.93­1.96, P = 0.113, respectively) (Table 3).
More specifically, females were 2 times more likely 
to risk facial lesions than males, and were almost 4 
times more likely to achieve a complete response than 
scalp ones.
Concerning local skin reactions, both the maximum 
levels and the values at day 2, 3, 8 and 15 of the 
composite score were associated with increased odds to 
achieve a complete response, ranging from 1.27 to 1.70.
Similarly, for erythema, both the maximum values 
and the levels at each follow up visit were associated 
with a complete response.
The maximum levels of crusting, swelling and 
vesiculation/pustulation gave also an increased odd to 
achieve a complete response, as well as the scores of 
swelling and vesiculation/pustulation at day 2 and 3 and 
of swelling and crusting at day 8.
Finally, ulceration at day 3 was also predictive of 
complete response to therapy.
Multivariate analysis
Multivariate backward logistic regression analysis 
showed that patients with facial lesions were almost 
5 times more likely to achieve a complete response 
than those treated on the scalp (OR = 5.19, 95%CI: 
1.51­17.86, P = 0.009); LSR composite score at day 
2 resulted as a predictive factor of complete response, 
with 14.6% higher odds for each point of score 
added (OR = 1.46, 95%CI: 1.08­1.97, P = 0.014). 
Furthermore, also the maximum level of LSR composite 
score was associated with complete response to in­
genol mebutate therapy, but with a lower statistical 
significance (OR = 1.50, 95%CI: 1.02­2.21, P = 0.038). 
Finally, regarding single scores, we found that patients 
with higher crusting reactions at day 8 were more likely 
to achieve a complete response, with 19.4% higher 
odds for each point of score added (OR = 1.94, 95%CI: 
1.18­3.20, P = 0.009) (Table 4).  
DISCUSSION
Ingenol mebutate gel was recently introduced as a safe 
and effective therapeutic option for non­hypertrophic 
non­hyperkeratotic AK at the dosage of 0.015% for face 
and scalp[14,15].
Phase Ⅲ trials reported complete clearance rates 
of 42.2% and partial response rates of 63.9%, for 
the treatment of facial and scalp AKs with ingenol 
mebutate, 5 however less is known about the factors 
influencing the response to treatment[16].
In the present study, we achieved complete and 
partial responses in 44.6% and 46.9% of cases, 
respectively; furthermore, ingenol mebutate 0.015% 
gel therapy resulted to be independently related to 
both the head site and the level of LSR, with a higher 
efficacy on facial lesions, compared to scalp ones and 
in case of more severe LSRs. Level of crusting at day 8 
was independently associated with the achievement of 
a complete response.
Table 3  Univariate logistic regression analysis
OR 95%CI for OR P value
Lower Upper
Gender 2.30 1.07   4.94    0.033a
Head site 4.07 1.53 10.83    0.005a
Max values LSR composite 1.55 1.27   1.89 < 0.001a
Erythema 3.90 1.86   8.19 < 0.001a
Crusting 1.85 1.18   2.92    0.008a
Swelling 2.24 1.50   3.35 < 0.001a
Vesiculation/pustulation 2.76 1.55   4.94    0.001a
Day 2 LSR composite 1.70 1.36   2.12 < 0.001a
Erythema 3.83 2.05   7.17 < 0.001a
Vesiculation/pustulation 2.82 1.74   4.56 < 0.001a
Swelling 2.73 1.64   4.55 < 0.001a
Day 3 LSR composite 1.65 1.34   2.05 < 0.001a
Erythema 3.90 1.86   8.19 < 0.001a
Vesiculation/pustulation 2.76 1.55   4.94    0.001a
Swelling 2.22 1.51   3.28 < 0.001a
Ulceration 1.72 1.06   2.79    0.028a
Day 8 LSR composite 1.25 1.07   1.47    0.006a
Erythema 2.44 1.45   4.13    0.001a
Swelling 1.55 1.06   2.25    0.022a
Crusting 1.76 1.17   2.64    0.006a
Day 15 LSR composite 1.27 1.02   1.59    0.030a
Erythema 1.93 1.22   3.05    0.005a
Day 29 Erythema 2.06 1.26   3.37    0.004a
Day 57 Erythema 2.03 1.01   4.09    0.047a
Factors predicting the response to ingenol mebutate 0.015% therapy. aP < 0.05. OR: Odds ratio; LSR: Local skin reaction.
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Previous studies showed a greater efficacy of 
ingenol mebutate on AKs located on the face compared 
to scalp lesions, but the reason has not been clarified 
so far. In our opinion a possible explanation could be 
related to the lower rate of self­application errors on 
face than on scalp; however, in the present study, we 
obtained the same results even performing a physician­
assisted application[17]. Therefore, other factors should 
be investigated to explain these findings, such as local 
differences in skin architecture, microbiota and ph.
Regarding the LSR composite score, we observed 
that both the highest levels and the values at day 2 
were independently associated to complete response. 
The vast majority of our study population reached the 
highest values of LSR composite score at day 2.
The weight of each component of the composite 
score at each follow up visit was further evaluated and 
related to drug efficacy.
Erythema was the only component present at each 
evaluation and it was closely associated with response 
in univariate logistic regression analysis. Intriguingly, in 
multivariate analysis, when the weight of each variable 
was mutually adjusted for all variables in the model, 
erythema no longer could be associated with the 
response to therapy.
The highest levels of swelling and vesiculation/
pustulation and the levels of these components reported 
in the first week after treatment were significantly 
associated to response in univariate analysis, but not in 
the multivariate model.
Conversely, the level of crusting at day 8 was 
the only single component of LSR composite score 
independently associated with the achievement of a 
complete response to ingenol mebutate therapy. A 
possible explanation of this finding could be related 
to the fact that the other parameters, in particular 
swelling and vesiculation/pustulation, probably reached 
their peak between day 3 and 8 follow up visits, so we 
couldn’t register the highest levels of these reactions. 
This is also supported by the fact that crusts are strictly 
related to the occurrence of vesicles and pustules, 
resulting from the drying of their fluid content.
Differently from phase Ⅲ trials in which the first 
follow up was set at day 4, we evaluated LSRs at day 2 
and 3, during physician­assisted application of ingenol.
Physician assisted application seems to be very 
effective in limiting withdrawal due to LSRs therefore 
improving adherence, in particular in elderly patients; 
however, a direct comparison with self­application was 
not performed.
Other limitations of the present study were the 
absence of long term efficacy, safety and cosmetic data, 
the absence of a quantitative evaluation of symptoms, 
such as pruritus, burn and pain and the low number 
of patients treated on the scalp, compared to the face 
group. However, facial localization demonstrated to 
be independently associated to complete response in 
multivariate analysis; whereas, this was not the case 
for patients treated on the scalp, due to the low number 
of patients that were treated. To obtain a more reliable 
result a test should be made on a higher number of 
patients.
On the basis of our findings we suggest that phy­
sician­assisted application of ingenol mebutate, at least 
for the first 2 d, could be very effective in order to 
improve adherence and patient satisfaction, maximize 
the results and minimize the risk of application errors. 
The severity of LSRs at day 2 and the level of crusting 
at day 8 should be considered as the best predictors of 
response to treatment.
In conclusion, our experience demonstrates that 
ingenol mebutate 0.015% gel is safe and effective when 
applied correctly. This treatment seems to be more 
effective on the face than on the scalp and the efficacy 
seems to be directly related to the level of LSR.
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(M), female (F); head site: Scalp, face; erythema at day 2, 3, 8, 15, 29, 57 
and max; crusting at day 8 and max; swelling at day 2, 3, 8 and max; 
vesiculation/pustulation at day 2, 3 and  max; ulceration at day 3; LSR 
composite at day 2, 3, 8, 15 and max. aP < 0.05. OR: Odds ratio; LSR: Local 
skin reaction.
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